Nov. 16 at 3:51 AM
$OMER Regarding NARSO price on launch, here are the recent Orphan and ultra-orphan FDA approved drugs on the market:
MESO: Ryoncil price
$155M, US patient pool 350
KRYS: VYJUVEK price
$630K, US patient pool 765
ABEO: Zevaskyn price
$3.1M, US patient pool 460(KRYS's competitor for DEB patients)
SLNO: VYKAT XR price
$466K, US patient pool 10k-20k
PGEN: PAPZIMEOS price
$460K, US patient pool 27000
Most relent to NARSO's TA-TMA is MESO's Ryoncil for pediatric SR-aGVHD, I am very confident of NARSO's price range of
$450-
$650K, more likely close to
$600K-
$650K, think in another way, if NARSO is approved only pediatric label,
NARSO may be priced in
$1.55M too, with Pediatric and adult label, NARSO in
$650K, 58% lower than Ryoncil, is fair, IMO.
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) is a serious complication after a stem cell transplant where the condition does not improve or worsens despite high-dose corticosteroid treatment.
